Chang Liu1,2,3, Christopher J Lyon1,3, Yang Bu3,4, Zaian Deng3,5, Elisabetta Walters6, Yan Li7, Liqun Zhang8, Anneke C Hesseling6, Edward A Graviss9, Ye Hu10,2,3. 1. Virginia G. Piper Biodesign Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ. 2. School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ. 3. Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX. 4. College of Materials Sciences and Opto-Electronics, University of Chinese Academy of Sciences, Beijing, China. 5. School of Biomedical Engineering, School of Ophthalmology and Optometry, The Eye Hospital, Wenzhou Medical University, Wenzhou, China. 6. Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. 7. Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. 8. Department of Tuberculosis, Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China. 9. Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Houston, TX. 10. Virginia G. Piper Biodesign Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ; tyhu@asu.edu.
Abstract
BACKGROUND: The diagnosis of active tuberculosis (TB) cases primarily relies on methods that detect Mycobacterium tuberculosis (Mtb) bacilli or their DNA in patient samples (e.g., mycobacterial culture and Xpert MTB/RIF assays), but these tests have low clinical sensitivity for patients with paucibacillary TB disease. Our goal was to evaluate the clinical performance of a newly developed assay that can rapidly diagnose active TB cases by direct detection of Mtb-derived antigens in patients' blood samples. METHODS: Nanoparticle (NanoDisk)-enriched peptides derived from the Mtb virulence factors CFP-10 (10-kDa culture factor protein) and ESAT-6 (6-kDa early secretory antigenic target) were analyzed by high-throughput mass spectrometry (MS). Serum from 294 prospectively enrolled Chinese adults were analyzed with this NanoDisk-MS method to evaluate the performance of direct serum Mtb antigen measurement as a means for rapid diagnosis of active TB cases. RESULTS: NanoDisk-MS diagnosed 174 (88.3%) of the study's TB cases, with 95.8% clinical specificity, and with 91.6% and 85.3% clinical sensitivity for culture-positive and culture-negative TB cases, respectively. NanoDisk-MS also exhibited 88% clinical sensitivity for pulmonary and 90% for extrapulmonary TB, exceeding the diagnostic performance of mycobacterial culture for these cases. CONCLUSIONS: Direct detection and quantification of serum Mtb antigens by NanoDisk-MS can rapidly and accurately diagnose active TB in adults, independent of disease site or culture status, and outperform Mycobacterium-based TB diagnostics.
BACKGROUND: The diagnosis of active tuberculosis (TB) cases primarily relies on methods that detect Mycobacterium tuberculosis (Mtb) bacilli or their DNA in patient samples (e.g., mycobacterial culture and Xpert MTB/RIF assays), but these tests have low clinical sensitivity for patients with paucibacillary TB disease. Our goal was to evaluate the clinical performance of a newly developed assay that can rapidly diagnose active TB cases by direct detection of Mtb-derived antigens in patients' blood samples. METHODS: Nanoparticle (NanoDisk)-enriched peptides derived from the Mtb virulence factors CFP-10 (10-kDa culture factor protein) and ESAT-6 (6-kDa early secretory antigenic target) were analyzed by high-throughput mass spectrometry (MS). Serum from 294 prospectively enrolled Chinese adults were analyzed with this NanoDisk-MS method to evaluate the performance of direct serum Mtb antigen measurement as a means for rapid diagnosis of active TB cases. RESULTS: NanoDisk-MS diagnosed 174 (88.3%) of the study's TB cases, with 95.8% clinical specificity, and with 91.6% and 85.3% clinical sensitivity for culture-positive and culture-negative TB cases, respectively. NanoDisk-MS also exhibited 88% clinical sensitivity for pulmonary and 90% for extrapulmonary TB, exceeding the diagnostic performance of mycobacterial culture for these cases. CONCLUSIONS: Direct detection and quantification of serum Mtb antigens by NanoDisk-MS can rapidly and accurately diagnose active TB in adults, independent of disease site or culture status, and outperform Mycobacterium-based TB diagnostics.
Authors: Chang Liu; Zhen Zhao; Jia Fan; Christopher J Lyon; Hung-Jen Wu; Dobrin Nedelkov; Adrian M Zelazny; Kenneth N Olivier; Lisa H Cazares; Steven M Holland; Edward A Graviss; Ye Hu Journal: Proc Natl Acad Sci U S A Date: 2017-03-27 Impact factor: 11.205
Authors: P N Brusasca; R Colangeli; K P Lyashchenko; X Zhao; M Vogelstein; J S Spencer; D N McMurray; M L Gennaro Journal: Scand J Immunol Date: 2001-11 Impact factor: 3.487
Authors: L Caviedes; T S Lee; R H Gilman; P Sheen; E Spellman; E H Lee; D E Berg; S Montenegro-James Journal: J Clin Microbiol Date: 2000-03 Impact factor: 5.948
Authors: Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins Journal: N Engl J Med Date: 2010-09-01 Impact factor: 91.245
Authors: Tobias Broger; Michael Tsionksy; Anu Mathew; Todd L Lowary; Abraham Pinter; Tatiana Plisova; Daniel Bartlett; Simone Barbero; Claudia M Denkinger; Emmanuel Moreau; Kiyonori Katsuragi; Masanori Kawasaki; Payam Nahid; George B Sigal Journal: PLoS One Date: 2019-04-18 Impact factor: 3.240
Authors: Laura Olbrich; Lisa Stockdale; Robindra Basu Roy; Rinn Song; Luka Cicin-Sain; Elizabeth Whittaker; Andrew J Prendergast; Helen Fletcher; James A Seddon Journal: PLoS Pathog Date: 2021-12-09 Impact factor: 6.823
Authors: Wenshu Zheng; Sylvia M LaCourse; Bofan Song; Dhiraj Kumar Singh; Mayank Khanna; Juan Olivo; Joshua Stern; Jaclyn N Escudero; Carlos Vergara; Fangfang Zhang; Shaobai Li; Shu Wang; Lisa M Cranmer; Zhen Huang; Christine M Bojanowski; Duran Bao; Irene Njuguna; Yating Xiao; Dalton C Wamalwa; Duc T Nguyen; Li Yang; Elizabeth Maleche-Obimbo; Nhung Nguyen; Lili Zhang; Ha Phan; Jia Fan; Bo Ning; Chenzhong Li; Christopher J Lyon; Edward A Graviss; Grace John-Stewart; Charles D Mitchell; Alistair J Ramsay; Deepak Kaushal; Rongguang Liang; Eddy Pérez-Then; Tony Y Hu Journal: Nat Biomed Eng Date: 2022-08-19 Impact factor: 29.234
Authors: Ruvandhi R Nathavitharana; Alberto L Garcia-Basteiro; Morten Ruhwald; Frank Cobelens; Grant Theron Journal: EBioMedicine Date: 2022-03-23 Impact factor: 11.205